Copy to clipboard 
MiMedx signed a definitive agreement to acquire Stability Biologics for US $10MM in cash and stock in a 60%/40% respective split. Stability BIologics provides human tissue products for the surgical, spine and orthopaedic industries. The transaction is expected to close in early 1Q16, and Stability Biologics will become a wholly-owned MiMedx subsidiary.
MiMedx expects full-year 2016 revenues of at least $15MM generated from Stability Biologics’ processed tissue and bone product distribution/sales.
Founded in 2010, Stability Biologics evolved from an initial focus on allograft distribution to a a focus on human tissue and bone product design and development, tissue processing and sales/distribution.
Stability Biologics’ proprietary platform of bioactive bone graft and tissue allografts comprises structural/particulate bone, tendons/ligaments, structural allografts, demineralized bone matrices, etc. Physio™ bone graft, its most recent launch, is 100% bone tissue with no added carrier. Its proprietary manufacturing process retains bioavailable growth factors, such as BMP 2, 4, 7 and VEGF, osteogenic proteins, and biologic calcium phosphate minerals.
MiMedx employs human amniotic tissue to develop and market advanced products and therapies for orthopaedic, spine, sports-medicine and other healthcare segments.
Source: MiMedx, Inc.
A number of biologics-focused transactions occurred in 2015, including:
- 4Q15: Bioventus’ acquisition of BioStructures; the formation of Kuros Biosciences from Kuros Biosurgery + Cytos Biotechnology
- 3Q15: Collagen Solutions’ acquisition of ChondroMimetic
- 1Q15: Ferring Pharmaceuticals’ acquisition of BioSurface Engineering Technologies
MiMedx signed a definitive agreement to acquire Stability Biologics for US $10MM in cash and stock in a 60%/40% respective split. Stability BIologics provides human tissue products for the surgical, spine and orthopaedic industries. The transaction is expected to close in early 1Q16, and Stability Biologics will become a wholly-owned MiMedx...
MiMedx signed a definitive agreement to acquire Stability Biologics for US $10MM in cash and stock in a 60%/40% respective split. Stability BIologics provides human tissue products for the surgical, spine and orthopaedic industries. The transaction is expected to close in early 1Q16, and Stability Biologics will become a wholly-owned MiMedx subsidiary.
MiMedx expects full-year 2016 revenues of at least $15MM generated from Stability Biologics’ processed tissue and bone product distribution/sales.
Founded in 2010, Stability Biologics evolved from an initial focus on allograft distribution to a a focus on human tissue and bone product design and development, tissue processing and sales/distribution.
Stability Biologics’ proprietary platform of bioactive bone graft and tissue allografts comprises structural/particulate bone, tendons/ligaments, structural allografts, demineralized bone matrices, etc. Physio™ bone graft, its most recent launch, is 100% bone tissue with no added carrier. Its proprietary manufacturing process retains bioavailable growth factors, such as BMP 2, 4, 7 and VEGF, osteogenic proteins, and biologic calcium phosphate minerals.
MiMedx employs human amniotic tissue to develop and market advanced products and therapies for orthopaedic, spine, sports-medicine and other healthcare segments.
Source: MiMedx, Inc.
A number of biologics-focused transactions occurred in 2015, including:
- 4Q15: Bioventus’ acquisition of BioStructures; the formation of Kuros Biosciences from Kuros Biosurgery + Cytos Biotechnology
- 3Q15: Collagen Solutions’ acquisition of ChondroMimetic
- 1Q15: Ferring Pharmaceuticals’ acquisition of BioSurface Engineering Technologies
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
